On Jan. 04, 2019, Full Federal
Circuit denied request of Acorda Therapeutics Inc’s for reconsideration of a
decision invalidating Ampyra® multiple sclerosis patents.
Previously on 9/10/18, Federal Circuit affirmed the Delaware
district court’s decision which found four patents invalid as obvious (reported here on this blog). In summary,
Court concluded that the dosing regimen contained in the claims of the four
patents would have been obvious to try considering the prior study designs and
also upheld the “blocking patent” analysis.
No comments:
Post a Comment